Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared ...
A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...
CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus ...
Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination ...